Literature DB >> 30165651

Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine.

Adriana Weinberg1, Zoran Popmihajlov2, Kenneth E Schmader3, Michael J Johnson1, Yupanqui Caldas1, Adriana Tovar Salazar1, Jennifer Canniff1, Barbara J McCarson2, Jason Martin2, Lei Pang2, Myron J Levin1.   

Abstract

Protection against zoster conferred by zoster vaccine live (ZVL; Zostavax) wanes over time. We compared varicella-zoster virus cell-mediated immunity (VZV-CMI) of adults ≥70 years who received a second dose of ZVL ≥10 years after the initial dose with de novo-immunized age-matched controls. Before and during the first year after vaccination, VZV-CMI was significantly higher in reimmunized compared with de novo vaccinees. At 3 years, VZV-CMI differences between groups decreased and only memory responses remained marginally higher in reimmunized participants. In conclusion, the increase in VZV-CMI generated by reimmunization with ZVL is at least equally persistent compared with de novo immunization.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30165651     DOI： 10.1093/infdis/jiy514

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  8 in total

1.  The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.

Authors:  Adriana Weinberg; Lei Pang; Michael J Johnson; Yupanqui Caldas; Alice Cho; Adriana Tovar-Salazar; Jennifer Canniff; Kenneth E Schmader; Zoran Popmihajlov; Myron J Levin
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

Review 2.  Aging and Options to Halt Declining Immunity to Virus Infections.

Authors:  Miguel Ángel Palacios-Pedrero; Albert D M E Osterhaus; Tanja Becker; Husni Elbahesh; Guus F Rimmelzwaan; Giulietta Saletti
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

Review 3.  Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change.

Authors:  Tamas Fulop; Anis Larbi; Graham Pawelec; Alan A Cohen; Guillaume Provost; Abedelouahed Khalil; Guy Lacombe; Serafim Rodrigues; Mathieu Desroches; Katsuiku Hirokawa; Claudio Franceschi; Jacek M Witkowski
Journal:  Vaccines (Basel)       Date:  2022-04-13

4.  Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence.

Authors:  Chester B Good; Natasha Parekh; Inmaculada Hernandez
Journal:  BMC Med       Date:  2018-12-18       Impact factor: 8.775

Review 5.  Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives.

Authors:  Angelika Wagner; Birgit Weinberger
Journal:  Front Immunol       Date:  2020-04-23       Impact factor: 7.561

Review 6.  Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly.

Authors:  Branca Pereira; Xiao-Ning Xu; Arne N Akbar
Journal:  Front Immunol       Date:  2020-10-14       Impact factor: 7.561

Review 7.  Alphaherpesvirus Vaccines.

Authors:  Clare Burn Aschner; Betsy C Herold
Journal:  Curr Issues Mol Biol       Date:  2020-09-23       Impact factor: 2.081

8.  The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.

Authors:  Alemnew F Dagnew; Nicola P Klein; Caroline Hervé; George Kalema; Emmanuel Di Paolo; James Peterson; Bruno Salaun; Anne Schuind
Journal:  J Infect Dis       Date:  2021-10-13       Impact factor: 5.226
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.